Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Behind the Clinical Trials for Non-Alcohol Fatty Liver Disease that Can Benefit 30% of Americans

The Impact Research Institute (IRI) is Waco, Texas’ resource for extending care options for NAFLD (non-alcohol fatty liver disease.) Nadege Gunn is IRI’s Medical Director and President. She joined Kevin Stevenson on I Don’t Care to discuss her and her team’s mission to treat NAFLD and other related diseases and conditions. Dr. Gunn is…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Promoted content from I Don't Care on MarketScale.

Share

The Impact Research Institute (IRI) is Waco, Texas’ resource for extending care options for NAFLD (non-alcohol fatty liver disease.) Nadege Gunn is IRI’s Medical Director and President. She joined Kevin Stevenson on I Don’t Care to discuss her and her team’s mission to treat NAFLD and other related diseases and conditions.

Dr. Gunn is a Gastroenterologist and Hepatologist whose main passion is the liver. “The liver is an amazing organ,” Dr. Gunn said. “It’s the only organ in the body that you could cut in half, and it can grow back in full size in about three months. The work we do in transplantation and replacing the liver is quite amazing, so that’s why I chose the field in general.”

Dr. Gunn helped open IRI in July of 2021. Necessity created the decision to develop the center. While practicing clinical trials in Austin, Texas, Dr. Gunn saw many patients traveling from the Waco area to receive treatment options for NAFLD. With no scan or clinical trial options available to people in Waco and the surrounding area, Dr. Gunn recognized an opportunity to open a clinic to serve the growing needs.

Community outreach is critical to the clinic’s role in Waco, TX. When they identify candidates who may have NAFLD, they do a non-invasive scan at the center to determine if the candidate does have the disease. “If they do, then we invite them to maybe participate in a clinical trial because there are no treatments for fatty liver,” Dr. Gunn said.

For people wondering if they might have NAFLD, Dr. Gunn said the disease is often asymptomatic in the early stages. “It is when the disease is progressing, when it is starting to injure and harm the liver, that people might start firstly feeling fatigued,” Dr. Gunn said. “They might feel pain in the right upper quadrant of their abdomen and their belly.” Recognizing these warning signs and seeking a diagnosis is critical before full-on cirrhosis of the liver occurs.

More Like This Story:

Providing Real-Time Feedback for Virtual Health

Tearing Down the Barrier of Prior Authorization Through Automation

I Don't Care

Part of this channel

I Don't Care

Candid healthcare leadership conversations with Kevin Stevenson

Visit the channel →

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Healthcare AI deployments stall on data quality, not model performance

Healthcare AI deployments stall on data quality, not model performance

Healthcare AI deployments are facing challenges not with the AI models themselves, but with the data quality. Hospital CIOs report difficulties in scaling AI due to fragmented and poorly governed data. This highlights the need for better data management and governance in healthcare AI initiatives.

  • 01Data quality is a major obstacle in scaling healthcare AI deployments.
  • 02Hospital CIOs are encountering issues with fragmented data governance.
  • 03AI model performance is not the primary challenge in these initiatives.

Jul 11, 2026

NHS commits £10bn to health tech, with ambient voice and pathology digitization at the center

NHS commits £10bn to health tech, with ambient voice and pathology digitization at the center

NHS England is investing £10bn in health technology, focusing on ambient voice technology and pathology digitization. This initiative aims to improve healthcare efficiency and patient outcomes. The commitment includes integrating advanced technologies into existing healthcare systems.

  • 01NHS England commits £10bn to health tech.
  • 02Focus areas include ambient voice technology and pathology digitization.
  • 03The initiative aims to enhance healthcare efficiency and patient care.

Jul 9, 2026

Canada launches Vital, a national hospital data platform backed by $210 million, starting with 160 hospitals

Canada launches Vital, a national hospital data platform backed by $210 million, starting with 160 hospitals

Canada has introduced a national hospital data platform named Vital, which will initially connect real-time data from 160 hospitals across three provinces. The initiative is supported by $210 million in funding, with coordination provided by Unity Health Toronto. This platform aims to enhance healthcare data integration and accessibility across the country.

  • 01Vital platform will connect 160 hospitals across three Canadian provinces.
  • 02The initiative is supported by $210 million in funding.
  • 03Unity Health Toronto is coordinating the implementation of this platform.

Jul 8, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub